Brief: Mabpharm Says Unit Entered Exclusive Commercialization Cooperation Agreement
13/04/2023 11:11
April 13 (Reuters) - Mabpharm Ltd 2181.HK :
* UNIT ENTERED EXCLUSIVE COMMERCIALIZATION COOPERATION
AGREEMENT
IN RELATION TO CMAB007 (OMALIZUMAB) IN CHINA
* AGREEMENT COVERS MAINLAND CHINA, HONG KONG, MACAU AND
TAIWAN
REGIONS
* TAIZHOU PHARMACEUTICAL GRANTED AN EXCLUSIVE PROMOTION
RIGHT IN
RESPECT OF CMAB007 IN CHINA TO JEMINCARE
* UNIT ENTERED AGREEMENT WITH JIANGXI JEMINCARE
PHARMACEUTICAL
Further company coverage: 2181.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mabpharm
See all newsBrief: Mabpharm Says NMPA Approves CMAB807X (Denosumab Injection) NDA
Brief: Mabpharm Says NMPA Approves Cmab807 (Denosumab Injection) NDA
Brief: Mabpharm FY Profit And Total Comprehensive Income Attributable Rmb57.1 Million
Brief: Mabpharm Says Approval From Drug Regulatory Authority Of Pakistan On Registration Of Core Product,CMAB008
Brief: Mabpharm Says Approval From Indonesian National Agency Of Drug And Food Control Of CMAB008